A5039423131- Inflammatory Bowel Disease
- Microscopic Colitis
- Diagnosis and treatment of tuberculosis
- Clostridium difficile and Clostridium perfringens research
- Colorectal Cancer Treatments and Studies
- Immunodeficiency and Autoimmune Disorders
- Eosinophilic Esophagitis
- Gastrointestinal motility and disorders
- Helicobacter pylori-related gastroenterology studies
- Primary Care and Health Outcomes
- Autoimmune and Inflammatory Disorders
- Health Systems, Economic Evaluations, Quality of Life
- Pregnancy and Medication Impact
- Liver Disease and Transplantation
- Liver Disease Diagnosis and Treatment
- Gastric Cancer Management and Outcomes
- Spondyloarthritis Studies and Treatments
- Gastroesophageal reflux and treatments
- Gut microbiota and health
- Diverticular Disease and Complications
- Cardiac, Anesthesia and Surgical Outcomes
- Pharmaceutical studies and practices
- Pediatric Pain Management Techniques
- Sirtuins and Resveratrol in Medicine
- Healthcare cost, quality, practices
Brigham and Women's Hospital
2019-2025
Harvard University
2019-2025
University of Southern Denmark
2025
Chestnut Hill College
2022-2023
Hospital of the University of Pennsylvania
2017-2019
University of Pennsylvania
2019
Fergusson College
2019
San Jose State University
2018
Brown University
2013-2017
Tata Memorial Hospital
2016
INTRODUCTION: The comparative effectiveness of upadacitinib and tofacitinib for ulcerative colitis (UC) is poorly understood. METHODS: In this retrospective cohort study, we compared steroid-free clinical remission (SFCR) endoscopic response/remission at 52 weeks among adults initiating or UC. RESULTS: A total 155 patients initiated (n = 81; 30% prior exposure) 74; 0% exposure). After inverse probability treatment-weighted logistic regression, was associated with significantly higher odds...
In 9 patients hospitalized for acute severe ulcerative colitis, 8 were successfully discharged without the need colectomy. Six of 7 with sufficient follow-up achieved steroid-free clinical remission at to 16 weeks, and 1 2 endoscopic response.
Objective Spondyloarthritis (SpA) is the most common extraintestinal manifestation of inflammatory bowel disease (IBD). The application screening tools to detect SpA in patients with IBD may lead earlier recognition and affect treatment decisions. Methods A combination two previously described questionnaires, DETAIL IBIS‐Q, was administered consecutive attending specialty clinics six U.S. academic medical centers. Demographic data, rheumatology history were extracted by chart review. Results...
Background/Aim: Spondyloarthritis (SpA), the most common extra-intestinal manifestation of inflammatory bowel disease (IBD), is reported in up to 39% patients with IBD. Despite this high prevalence, risk factors for developing SpA IBD are not well described. In study, we aimed determine associated symptoms and their prevalence an cohort. Methods: Two validated screening questionnaires detection (DETAIL = DETection Arthritis Inflammatory boweL diseases, IBIS-Q Identification Questionnaire)...
ABSTRACT Fecal microbiota transplantation (FMT) prevents recurrent Clostridioides difficile infections (rCDI) in patients with inflammatory bowel disease. Bezlotoxumab is also indicated to prevent rCDI. We assess the impact of FMT combination bezlotoxumab disease and conducted a multicenter randomized placebo-controlled trial. All received single colonoscopic FMT. Patients were 1:1 receive or placebo. Sixty-one enrolled (30 treatment 31 placebo). Overall, 5 participants (8%) experienced CDI...
Abstract Background Many patients with Crohn’s disease (CD) who lose response to the standard ustekinumab dose interval of every 8 weeks (q8w) undergo intensification q4w or q6w. However, baseline factors that predict success failure after are unknown. We sought identify predictors for CD. Methods This was a retrospective cohort study adult CD undergoing at tertiary referral center between January 1, 2016, and 31, 2019. Electronic health records were reviewed obtain patient demographics,...
Background: A significant proportion of patients with Crohn’s disease (CD) and ulcerative colitis (UC) become opioid users, but data pertaining to predictors chronic use remain sparse. Objective: We examined for in CD/UC. Design: nationwide cohort study based on Danish registries, comprising incident CD/UC (≥ 18 years) from January 1, 1996-December 31, 2021. Chronic was defined as > 1 prescriptions at least two three consecutive quarters. Cox regression models were used estimate adjusted...
Over the last decade, therapies for moderate-to-severe ulcerative colitis (UC) have expanded to target not only tumor necrosis factor-alpha (TNF-α; infliximab, adalimumab, golimumab) agents but also α 4β 7 integrin (vedolizumab), interleukins 12 and 23 (ustekinumab), Janus kinase inhibitors (tofacitinib). However, head-to-head clinical trials comparing these are limited,1 optimal positioning of biologics is an area ongoing investigation. A recent meta-analysis identified infliximab as...
Lay Summary In this case series, 6 patients with chronic pouchitis (n = 3), cuffitis 2), or Crohn’s-like disease of the pouch 1) were treated tofacitinib. One patient achieved clinical response; however, all ultimately discontinued therapy due to nonresponse adverse events.
Lay Summary In this retrospective cohort study, we demonstrated that dose intensification of ustekinumab to every 4 or 6 weeks was effective in both achieving and maintaining clinical remission for >40% inflammatory bowel disease patients up 24 months.
Summary Background The risk of chronic opioid use after surgery for Crohn's disease (CD) is not known. Aim aim this study to examine the according age at time and prior surgery. Methods This nationwide cohort included patients with a first CD (January 1, 1996 through 2021). We examined prescribed opioids 9 months estimated adjusted odds ratios (OR) in elderly (≥60 years), adults (≥40 <60 young (≥18 <40 years) Chronic was defined as prescriptions least two three consecutive quarters....
Up to 10% of patients with ulcerative colitis (UC) require total proctocolectomy (TPC) within 10 years after diagnosis.1 Ileal pouch-anal anastomosis (IPAA) is the preferred operation in this population. However, chronic pouch disorders (CPDs), including antibiotic-refractory pouchitis (CARP) and Crohn's disease (CDoP), may occur up 30% IPAA, respectively.2 Patients refractory CPDs often biologic therapy or excision.3 Ustekinumab (UST) an anti-interleukin approved for UC CD. Limited data...
Abstract Background Tofacitinib is an oral JAK inhibitor for the treatment of ulcerative colitis (UC). We assessed outcomes through 78 weeks tofacitinib therapy UC in a real-world setting. Methods This retrospective cohort study included adults initiating from May 1, 2018, to April 2021, at large academic center United States. The primary outcome was steroid-free clinical remission (+/-4) (SFCR 78; simple activity index ≤2 with no corticosteroid use within 30 days). secondary discontinuation...
Teaching hospitals are known for higher inpatient costs compared to community centers. We therefore assessed the impact of hospital teaching status on IBD hospitalization outcomes and found that increased resource utilization is driven by disease complexity, not status.
Abstract Background Tofacitinib is an oral Janus kinase inhibitor for the treatment of ulcerative colitis (UC). Real-world data comparing effectiveness tofacitinib to ustekinumab are limited. We compared 52-week outcomes vs UC after antitumor necrosis factor (anti-TNF) failure. Methods In this retrospective cohort study, adults initiated or anti-TNF failure May 1, 2018 April 2021, at a US academic medical center. The primary outcome was steroid-free clinical remission (SFCR) 12 and 52 weeks....